"Canine lymphoma is a blood born disease that creates tumors in any part of the body that it can get to containing lymph tissue. This tissue resides in almost all of the major organs, the lymph nodes, and even in the liver.
While the cause of this disease is not known, it is known that the most common dogs to contact canine lymphoma are golden retrievers. Most middle aged dogs are at a higher risk for contracting lymphoma, but golden retrievers have the highest possible risk.
Unlike canine leukemia, lymphoma can be treated with surgery and oral chemotherapy treatments. The good thing is that less than 10% of dogs that have lymphoma ever get any kind of side effects from the chemo treatments. The only real side effects that you might notice are the loss of hair, appetite, and sometimes diarrhea. While the chemo therapy won’t cure the lymphoma, there is a good chance that your dog will go into remission and the lymphoma won’t come back."
Read More: http://www.buzzle.com/articles/things-to-know-about-canine-lymphoma.html
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...